Article Text

Download PDFPDF
Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?
  1. Roy Fleischmann1,
  2. Yusuf Yazici2
  1. 1Department of Medicine, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, Texas, USA
  2. 2Department of Medicine, New York University School of Medicine, NYU Hospital for Joint Diseases, New York, USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We have read with interest the article by Schiff et al1 comparing oral with subcutaneous administration of methotrexate (MTX). The authors, as one would have predicted, have shown that there is higher bioavailability of subcutaneous MTX compared with oral administration.2–4

We are somewhat confused, however, with the interpretation of some of the data.

First, Figure 1 in the article clearly shows that there is an increase in area under the curve (AUC) of MTX with an increase in dose of subcutaneous MTX up to 25 mg. The authors state that with an oral dose of MTX, the AUC plateaus at 15 mg. Yet, in figure 1, it appears there is an increase in AUC of oral MTX 15 mg from approximately 1850 ng.h/mL to approximately 2000 ng.h/mL with 20 mg of oral MTX. The recommended dose of MTX is …

View Full Text


  • Handling editor Tore K Kvien

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles